pages · PDF
The gut wall is an active immune organ — ~70% of immune tissue sits behind it. When tight junctions fail, undigested protein, bacterial LPS, and inflammatory fragments leak into circulation and drive IBS, fatigue, autoimmunity, skin reactivity, anxiety, and brain fog from one upstream substrate. The peptide protocol — oral BPC-157 + oral KPV + short-cycle SubQ LL-37 — addresses the three distinct failures: barrier disruption (tight-junction loss), NF-κB inflammatory storm, and biofilm-protected dysbiosis. Research describes Calprotectin normalization and symptom resolution in a meaningful majority at 12 weeks.
Unlock: Gut Healing — IBS / Leaky Gut Reversal Quick-Start
Enter your details to get instant access to this free guide.
No spam. We respect your privacy.
“These guides saved me weeks of research. The evidence ratings alone changed how I approach my protocols.”
-- Verified DoseCraft user
Why this matters
If you've been told IBS is something you manage with low-FODMAP and antispasmodics for life — the literature describes a different model. The gut wall is not a passive tube. It's an active immune organ — roughly 70% of the body's immune tissue sits behind it. When the tight junctions between intestinal epithelial cells break down, undigested proteins, bacterial endotoxins, and inflammatory fragments enter circulation and trigger a body-wide cascade linked to IBS, fatigue, autoimmunity, skin conditions, anxiety, and brain fog — all from the same upstream failure. Research describes a targeted peptide approach addressing the gut barrier at the cellular level, and clinical practitioners report a meaningful majority of patients achieving symptom resolution alongside measurable barrier-marker normalization. No bro-science. No name-drops.
What you'll learn
- Why IBS is fundamentally a gut-barrier failure, not a motility disorder or a 'food sensitivity'
- How tight-junction protein loss (ZO-1, occludin, claudin-1) drives the leaky-gut cascade into systemic inflammation
- Why oral BPC-157 is the correct route for gut healing — and why this is NOT the same as oral BPC-157 for systemic conditions
- How KPV locks NF-κB in the off position at the intestinal epithelium and shifts macrophages from M1 (inflammatory) to M2 (repair)
- Why LL-37 is the missing piece for biofilm-protected dysbiosis — and why the 4–6 week cycle is non-negotiable
- How the gut-brain axis carries inflammatory signal via the vagus nerve to drive anxiety and brain fog from a downstream-of-gut substrate
- What Calprotectin, Zonulin, and secretory IgA tell you about barrier status and protocol response
- What to expect at weeks 2, 4, 8, and 12 in symptom resolution and barrier-marker movement
The protocol at a glance
Dose
BPC-157 500 mcg oral (capsule, empty stomach) · KPV 500 mcg oral · LL-37 50–100 mcg SubQ
Frequency
BPC-157 2× daily · KPV 2× daily · LL-37 daily
Cycle
BPC-157 + KPV: 8–12 weeks on / 2–4 weeks off · LL-37: strict 4–6 week maximum per cycle (preserves beneficial gut flora); maximum 2 cycles per year. KPV cycles 4–6 weeks on / 2–4 weeks off when used long-term to prevent melanocortin (MC1R/MC3R) receptor desensitization · Reassess Calprotectin + Zonulin at weeks 8 and 12.
Timeline
Symptom improvement (bloating, urgency, post-meal reactivity): 2–4 weeks · NF-κB pathway suppression: 1–2 weeks · Tight-junction restoration: 4–8 weeks · Full mucosal healing: 8–12 weeks · Calprotectin normalization: 12 weeks
Cautions
Oral BPC-157 is the correct route for gut healing — it acts LOCALLY on the GI mucosa, not systemically. This is the carve-out: for any non-gut indication (tendon, joint, brain, systemic inflammation) BPC-157 must be injected SubQ — oral administration produces no measurable systemic effect because the peptide is degraded by gastric proteases and first-pass liver metabolism. The gut indication is the one case where that 'failure' is the feature. LL-37 cycles are strict 4–6 week maximum because longer exposure disrupts beneficial gut flora alongside the targeted pathogens. KPV cycles 4–6 weeks on / 2–4 weeks off prevent melanocortin receptor desensitization. If on immunosuppressive biologics for IBD (Humira, Remicade, Stelara, etc.) coordinate with your gastroenterologist before adding any of these compounds. This is a research synthesis, not medical advice.
Is this for you?
- Adults with diagnosed IBS (Rome IV criteria) — IBS-D, IBS-C, or IBS-M phenotypes
- Users with confirmed elevated intestinal permeability (zonulin elevated, or symptomatic leaky-gut phenotype)
- Anyone with mild-to-moderate IBD in remission seeking to maintain remission and reduce flare frequency
- Users with post-antibiotic dysbiosis, post-acute-gastroenteritis IBS, or food-poisoning-triggered gut dysfunction
- Adults with downstream gut-driven systemic symptoms (brain fog, fatigue, skin reactivity, anxiety) suspected to trace upstream to barrier failure
- Active severe IBD flare — clinical-primary care first; this is for maintenance/remission, not acute rescue
- Active GI malignancy or recent GI cancer — BPC-157 angiogenic effect requires oncology sign-off
- Pregnancy or breastfeeding
- Currently on immunosuppressive biologics (Humira, Remicade, Stelara) without gastroenterologist coordination
- Under 21 years of age
The mechanism — why it works
Tight-junction failure — the upstream model
Standard-of-care frames IBS as a motility disorder or 'functional' bowel condition with no identifiable structural cause. The literature describes a measurable structural failure: disruption of the intercellular tight junctions between intestinal epithelial cells. Tight-junction proteins — ZO-1 (zonula occludens-1), occludin, and the claudin family — form the molecular seal between epithelial cells. When this seal degrades, undigested protein fragments, bacterial lipopolysaccharide (LPS), and inflammatory metabolites cross from gut lumen into circulation. The immune system encounters these signals, mounts a response, and a chronic systemic inflammatory cascade is established. A 2019 study described elevated zonulin (the protein that regulates tight-junction opening) in 81% of IBS-D patients vs controls — biological confirmation that 'functional' bowel disease has a structural substrate.
KPV — the NF-κB lock at the intestinal epithelium
KPV is a tripeptide derived from the C-terminus of alpha-melanocyte stimulating hormone (alpha-MSH). Despite being only three amino acids, it retains the full anti-inflammatory potency of the parent hormone. Mechanism: KPV prevents Nuclear Factor kappa-B (NF-κB) translocation from cytoplasm to nucleus — locking the master inflammatory switch in the off position. NF-κB controls expression of over 400 inflammatory genes including the IL-6, TNF-α, and IL-1β cytokine cascade that perpetuates intestinal inflammation. Research describes KPV reducing colonic inflammation scores in ulcerative colitis cohorts and decreasing mucosal TNF-α and IL-6 measurably within 72 hours. The 4–6 week on / 2–4 week off cycling preserves MC1R/MC3R receptor sensitivity — continuous exposure causes melanocortin receptor desensitization that erodes the effect over time.
BPC-157 — physical barrier restoration (oral carve-out)
BPC-157 is the master signal caller for the VEGF system and tight-junction repair. The peptide upregulates ZO-1 and occludin expression substantially — research describes restored intestinal barrier integrity through this receptor signaling. Here is the critical nuance: oral BPC-157 is the correct route for gut indications and the wrong route for everything else. The peptide is degraded by gastric proteases and first-pass liver metabolism, so it cannot deliver systemic concentrations — which is precisely why oral administration is therapeutic for the gut: the peptide acts LOCALLY on the GI mucosa during the brief window before degradation. For tendon, joint, brain, or systemic-inflammation indications BPC-157 must be injected SubQ. For the gut, oral is the route. This is the one case in the entire compound library where the gut-localized effect is the feature rather than a limitation.
BPC-157 + KPV synergy — physical seal + signal lock
The two compounds address different mechanisms and stack synergistically. KPV is the signal-layer intervention — it shuts off the NF-κB cytokine storm that's chronically activated. BPC-157 is the physical-layer intervention — it rebuilds the tight-junction proteins that are missing. Without KPV, BPC-157 is repairing a structure that keeps getting torn down by ongoing inflammation. Without BPC-157, KPV is calming a fire above a foundation that's still cracked. Together they address both the cause and the structural consequence. Clinical practitioners report this combination producing more complete barrier restoration than either compound alone — a pattern measurable on zonulin and calprotectin endpoints.
LL-37 — biofilm disruption underneath the dysbiosis
Chronic dysbiosis is rarely just 'too many bad bugs.' The pathogenic species form biofilms — structured communities encased in a polysaccharide matrix that shields them from antibiotics, host immune cells, and antimicrobial peptides. This is why rotating antibiotics produce temporary improvement followed by relapse: the biofilm reservoir reseeds the population every time. LL-37 is the only human cathelicidin antimicrobial peptide. It dissolves bacterial biofilms at a structural level — penetrating the polysaccharide matrix, disrupting bacterial cell membranes, and exposing pathogens to host immune clearance. This is what addresses the dysbiosis layer that BPC-157 and KPV alone cannot reach. Critically: the strict 4–6 week cycle maximum exists because LL-37 is broad-spectrum — extended exposure disrupts beneficial commensal flora alongside the targeted pathogens. Two cycles per year is the conservative ceiling.
Gut-brain axis — why gut healing resolves downstream symptoms
The vagus nerve is a bidirectional communication line between gut and brain. When the intestinal epithelium is inflamed, vagal afferents transmit the signal to the central nervous system in real time — driving the brain fog, anxiety, low mood, and post-meal cognitive slumps that gut-dysfunction patients describe as 'foggy after eating.' The mechanism is direct: gut-derived IL-6 and TNF-α activate microglia in the brain; intestinal-derived LPS crossing a leaky barrier into circulation drives systemic neuroinflammation. This is why patients on this protocol frequently describe cognitive and mood improvements as the first wave of subjective benefit — often within 2–3 weeks, before the gut symptoms themselves fully resolve. The gut signal is upstream of the brain symptom; address the gut, the brain follows.
Mucosal immune rebalancing — M1 to M2 macrophages
The intestinal lamina propria contains the largest population of macrophages in the body. In a healthy gut these macrophages exist predominantly in the M2 (tolerogenic, repair-oriented) phenotype. In inflamed gut they shift toward M1 (cytotoxic, inflammatory) — producing the cytokines that perpetuate barrier disruption. KPV is research-described as shifting macrophage polarization back toward M2 via the melanocortin receptor pathway. BPC-157 amplifies this through IL-10 upregulation. The combined effect is restoration of mucosal immune tolerance — the gut immune system stops treating normal contents as threats. This is the immunological endpoint that distinguishes 'managed' from 'reversed' — measurable on the Calprotectin / fecal lactoferrin / secretory IgA panel.
Foundational levers (not optional)
The research describes each as an independent driver. The protocol reduces their negative impact but doesn't eliminate it.
Eliminate the obvious irritants first
Alcohol, NSAIDs, and high-dose caffeine directly disrupt tight junctions. The protocol cannot fully compensate for daily NSAID use or heavy alcohol. Run a 2-week washout of these before starting if possible — many patients see baseline improvement before the peptides have any effect.
Adequate dietary fiber from diverse sources
The repair process feeds on short-chain fatty acids (butyrate, propionate, acetate) produced by commensal flora fermenting fiber. 25–35 g/day from diverse plant sources is the research-described floor. Restrictive low-FODMAP elimination is a temporary diagnostic tool — not a long-term substrate for gut healing. Reintroduce systematically as the protocol progresses.
Stress and the HPA-axis amplifier
Cortisol directly increases intestinal permeability. Chronic HPA-axis activation perpetuates the same barrier failure the peptides are trying to repair. Vagal-tone work (slow nasal breathing, cold exposure, gargling), 7+ hours of sleep, and stress-reduction practice are not optional adjuncts — they're the upstream lever the protocol amplifies.
Sleep architecture
Mucosal repair happens predominantly during slow-wave sleep — the same window that drives systemic GH secretion. Under-slept patients on this protocol consistently respond more slowly. 7–8 hours with intact deep sleep is the substrate the peptide protocol operates on.
What you'll feel — week by week
Days 1–7
KPV's NF-κB suppression begins within 72 hours. Many users describe reduced systemic 'on-fire' feeling, less brain fog after meals, and lower joint stiffness within the first week. Bloating frequency often starts decreasing. The cognitive-clarity shift typically precedes the gut-symptom shift — that's the gut-brain axis responding to inflammation reduction.
Weeks 2–4
Gut symptoms begin meaningful improvement. Post-meal reactivity (bloating, urgency, abdominal pain) typically eases first. Stool frequency and consistency normalize. BPC-157's tight-junction repair is underway but the structural changes haven't fully manifested yet — the subjective improvement here is mostly inflammation reduction, not yet barrier restoration. LL-37 effect on dysbiosis-driven symptoms (especially in SIBO/dysbiosis-overlay phenotypes) typically shows in this window.
Weeks 6–8
First objective barrier-marker recheck. Zonulin trending toward normal. Calprotectin dropping if elevated at baseline. Secretory IgA stabilizing. Most users describe being able to tolerate previously-triggering foods in moderation — the food-sensitivity layer is downstream of barrier failure, so as the barrier closes the reactivity narrows. End the LL-37 cycle here unless extended under practitioner guidance.
Weeks 10–12
Full protocol endpoint. Compare Calprotectin and Zonulin to baseline. The research describes meaningful normalization in a substantial majority of patients on the full combined protocol. Mucosal healing is structurally complete for most users. Decide: maintenance protocol (BPC-157 oral 500 mcg 1×/day + KPV 500 mcg oral 1×/day for 8–12 weeks, then taper) vs second full cycle for residual symptoms vs full taper with diet and lifestyle as the maintenance substrate.
What could go wrong
Common (no action)
- Mild loose stools in BPC-157 + KPV week 1 — adaptation to mucosal signaling change; resolves within 5–7 days
- Transient herxheimer-like reaction with LL-37 in days 2–5 (bloating, fatigue, headache) — bacterial die-off pattern; hold dose steady, typically resolves
- Mild appetite changes — GI signaling normalization; benign
- Vivid dreams in week 1 — reported by minority; resolves
Watch + adjust
- Gut symptoms worsening rather than improving after week 2 — reassess compliance, food triggers, and stress load before adjusting dose
- Persistent herxheimer-like reaction beyond week 1 on LL-37 — reduce to every-other-day dosing for the rest of the cycle
- New unexplained symptoms (rash, joint pain, fever) — pause and reassess; possible immune reaction
Stop + seek care
- Severe abdominal pain, fever, or bloody stools — stop immediately, seek clinical evaluation (rule out IBD flare or infection)
- Allergic reaction at LL-37 injection site (hives, swelling, difficulty breathing) — emergency care
- Any GI bleeding or signs of obstruction — emergency evaluation
Bloodwork — what to track
Primary outcome markers: Calprotectin (stool; target < 50 µg/g — intestinal inflammation), Zonulin (serum or stool; target trending toward normal range — tight-junction integrity), Secretory IgA (stool; target age-appropriate range — mucosal immune competence). Supporting panel: hs-CRP (target < 1.0 mg/L — systemic inflammation tracking), CBC with differential (rule out occult infection or anemia), comprehensive stool test (GI-MAP or equivalent — dysbiosis pattern, biofilm markers, parasitology) at baseline and week 12. Symptom diary (Bristol stool chart + daily symptom severity) is as important as bloodwork for this condition. Full bloodwork target table + tracker worksheet in the paid pack.
Frequently asked
Why is oral BPC-157 right for the gut but wrong for everything else?
BPC-157 is degraded by gastric proteases and first-pass liver metabolism — that's why oral administration produces no measurable systemic effect. For tendon, joint, brain, or any non-gut indication, this degradation is a failure mode and SubQ injection is the only effective route. For the gut, that degradation IS the feature: the peptide acts locally on the GI mucosa during the brief window before it's broken down. The 'oral BPC-157 doesn't work' rule applies to systemic indications. Gut healing is the carve-out — and it's the one case in the entire compound library where oral is the correct route.
Do I really need LL-37, or can I run just BPC-157 + KPV?
If your phenotype is straightforward leaky-gut / mild IBS without significant dysbiosis or biofilm-protected pathogens, BPC-157 + KPV alone is often sufficient and is the research-described conservative starting protocol. Add LL-37 when: GI-MAP or stool culture shows confirmed dysbiosis, prior antibiotics produced temporary improvement followed by relapse (classic biofilm pattern), or symptoms persist after 8 weeks on BPC-157 + KPV. Never extend LL-37 beyond 6 weeks per cycle — disrupting commensal flora is the failure mode that turns a healing protocol into a worsening one.
I have IBD and I'm on Humira / Remicade / Stelara. Can I run this?
Coordinate with your gastroenterologist before starting. The combination is not categorically contraindicated, but the immunological interactions are not characterized in published interaction studies. KPV's NF-κB inhibition and the biologic's TNF-α blockade work on related pathways — additive effect is theoretical but the literature describing this specific combination is thin. This is exactly the case where a practitioner-coordinated protocol is non-negotiable.
Can I keep eating low-FODMAP / gluten-free / dairy-free during the protocol?
Yes, but restrictive elimination is a diagnostic and acute-symptom-management tool — not a substrate for gut healing. Severe long-term low-FODMAP starves the commensal flora that produce the short-chain fatty acids (butyrate, propionate) the protocol relies on. Use elimination tactically: identify clear triggers, eliminate during the acute weeks 1–4, then systematically reintroduce as barrier function recovers. By week 8 most users tolerate substantially more variety than at baseline.
IBS Is Reversible — what does 'reversible' actually mean here?
Reversal means: Calprotectin in the normal range, Zonulin trending toward normal, symptom resolution stable off the protocol on a non-restrictive diverse diet, and no symptomatic relapse on continued lifestyle maintenance (sleep, stress, fiber diversity). Research describes this outcome in a meaningful majority of IBS and mild IBD-in-remission patients on the full combined protocol. It's not guaranteed. It is what the literature describes as achievable — categorically different from the standard framing that IBS is a lifelong functional condition you manage forever.
Why do I feel mentally clearer before my gut symptoms improve?
That's the gut-brain axis responding to inflammation reduction faster than the structural barrier repair completes. KPV suppresses NF-κB cytokine production within 72 hours — that cytokine load is what was driving the brain fog, post-meal cognitive slumps, and low-grade anxiety via vagal-nerve signaling. The gut symptoms require the slower structural barrier repair (BPC-157's tight-junction work, 4–8 weeks). It's standard for the cognitive layer to clear first.
Cited research
Verified Vendors
Where to get these compounds
Oral BPC-157 and oral KPV capsules are MyOasis Labs' core catalog — broader oral-capsule formulary suits gut-localized dosing. LL-37 is injectable (SubQ). Source all three from the verified vendor below; confirm third-party batch testing. Reconstitution worksheet for LL-37 included in the bloodwork pack.
Peptide Partners
Practitioner-tier research peptides
HPLC + Mass-Spec verified · Free replacement on failed third-party tests
MyOasis Labs
Widest catalog — injectables, oral caps, blends
Third-party lab tested · Every batch
Hydro Research Peptides
Research-grade peptides — 20% off your order
Research peptides · newest addition to the verified roster
Affiliate disclosure: DoseCraft earns a small commission on orders made through these vendor links — at no extra cost to you. We only partner with vendors that pass our internal vendor-rubric audit.
Ready for the full experience?
DoseCraft gives you AI-powered protocol building, 90+ compound library, dose tracking, and evidence-rated stacks from leading practitioners.
Get Started — Try DoseCraft NowNot medical advice — educational only. These guides are for informational and research purposes only. Always consult a licensed healthcare professional before starting any peptide protocol.